BiologicalDrug
RC28-E protein clinical trials
- studies test it
- 4
- open now
- 2
- in phase 3
- 2
- first study started
- 2019
Keep track of what changes. Save the RC28-E protein studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 1
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses RC28-E protein is read from its arms, and is right about nine times in ten.
Testing it · 4
- Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular EdemaRecruitingPhase 3RemeGen Co., Ltd.NCT05885503Written as RC-28E
- Efficacy and Safety of RC28-E Versus AfliberceptRecruitingPhase 3RemeGen Co., Ltd.NCT05727397Written as RC28-E
- Evaluation of RC28-E Injection in Diabetic RetinopathyStatus unknownPhase 2RemeGen Co., Ltd.NCT04782128Written as RC28-E injection
- Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular DegenerationCompletedPhase 1RemeGen Co., Ltd.NCT03777254Written as RC28-E
Codes
What other systems call RC28-E protein · ClinicalTrials.gg INT001425
- MeSH (NLM) C000710674RC28-E proteinOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710674 | RC28-E protein | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.